Stocks
GlaxoSmithKline (GSK) Debt/EBITDA US GAAP (year values) |
|||||||||
| FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | LTM ? | CAGR 5 years ? | |||
| Debt/EBITDA | 4.14 | 1.52 | 1.80 | 1.99 | 1.37 | 1.83 | |||
| Changes by years, y/y, % | +18% | -63% | +18% | +10% | -31% | -17.2% | |||
GlaxoSmithKline. Debt/EBITDA
GlaxoSmithKline. Debt/EBITDA, changes, %
GlaxoSmithKline (GSK) Debt/EBITDA US GAAP (quarter values) |
||||||||
| FY2025Q2 | FY2025Q3 | FY2025Q4 | FY2025Q4 | FY2026Q1 | LTM ? | |||
| Debt/EBITDA | 2.19 | 1.80 | 1.23 | 1.23 | 1.83 | 1.83 | ||
| Changes by years, y/y, % | +0% | -6% | -38% | -38% | -22% | |||
| Changes by quarters, q/q, % | -7% | -18% | -32% | 0% | +48% | |||
